Clinical perspective, offered as context rather than as advice.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

TirzTom said:

MASHdoc_SA said: ...we don't know the long-term effects of cardiovascular risk...

Saving this. It is the first explanation that did not require me to already understand it. Adding it to my notes with a link back to this thread.

Clinical perspective, offered as context rather than as advice.

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 6.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 1.5 mg/L (moderate risk)
Month 12 hsCRP: 0.3 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 13% to 4%. My cardiologist is genuinely impressed.

LindaRN_retired said:

CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 6.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

Adding a me-too, because a thread of one person's experience is not much use.

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Tagging this one for the weekly digest.